Skip to main content

Table 1 Characteristics of eligible trials

From: Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment: a meta-analysis

Author (Study) Year Intervention Dosage of treatment Duration (yr) Number of patients Follow-up (mo)
Gnant (ABCSG12) 2009 Zoledronic acid
No treatment
4 mg IV every 6 months 3 899
904
47.8
Shapiro (CALGB) 2011 Zoledronic acid
No treatment
4 mg IV every 3 months NA 70
80
12
Hershman 2008 Zoledronic acid
Placebo
4 mg IV every 3 months 1 50
53
12
Coleman (AZURE) 2011 Zoledronic acid
No treatment
4 mg IV monthly for 6 months, then every 3 months for 8 doses and then every 6 months for 5 doses 5 1665
1675
6
Brufsky (Z-FAST) 2009 Upfront zoledronic acid
Delayed zoledronci acid
4 mg IV every 6 months 5 300
300
36
Eidtmann (ZO-FAST) 2010 Upfront zoledronic acid
Delayed zoledronci acid
4 mg IV every 6 months 5 524
536
36
Hines (N03CC) 2009 Upfront zoledronic acid
Delayed zoledronci acid
4 mg IV every 6 months 5 267
274
12
  1. yr, year; mo, months; IV, intravenous; NA, not available